RESMED Business Summary

ResMed Inc. (RMD) operates a dual-revenue business model centered on the manufacturing of medical devices and the provision of cloud-connected software-as-a-service (SaaS) solutions. The company generates revenue through the high-volume sale of therapeutic hardware, including Continuous Positive Airway Pressure (CPAP) machines and ventilators, alongside a recurring stream of high-margin sales from masks and accessories. Its operations are divided into two primary segments: Sleep and Breathing Health, which encompasses its core respiratory devices and consumables, and Residential Care Software (RCS), which provides end-to-end management platforms for out-of-hospital care providers. ResMed maintains a dominant global market position, leveraging its digital health ecosystem of over 140 countries to outperform direct competitors such as Fisher & Paykel Healthcare, BMC Medical, and Philips Respironics, the latter of which has struggled to regain share following significant product recalls. The company was founded in 1989 by Dr. Peter C. Farrell, who currently serves as Chairman Emeritus and was recently honored with the 2026 Horatio Alger Award for his contributions to medical technology. Leadership is currently spearheaded by CEO and Chairman Michael "Mick" Farrell, who brings over 25 years of experience at the firm and previously held senior roles at Sanofi Genzyme and Dow Chemical. The executive team includes long-standing CFO Brett Sandercock, Chief Product Officer Justin Leong, and newly appointed Chief Strategy Officer Kylie Canaday (January 2026). ResMed’s board is characterized by deep technical and clinical expertise, featuring notable members such as Dr. Desney Tan, a former Microsoft Research executive, and Nicole Mowad-Nassar of AbbVie. The company is backed by significant institutional investors, including Allianz Asset Management and WCM Investment Management, supporting its aggressive capital allocation strategy focused on AI-driven innovation and share repurchases.